financetom
Business
financetom
/
Business
/
Telephone & Data Systems Insider Sold Shares Worth $1,027,476, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Telephone & Data Systems Insider Sold Shares Worth $1,027,476, According to a Recent SEC Filing
Aug 18, 2025 2:06 PM

04:34 PM EDT, 08/18/2025 (MT Newswires) -- Vicki L Villacrez, Director, Executive Vice President & CFO, on August 18, 2025, sold 26,334 shares in Telephone & Data Systems (TDS) for $1,027,476. Following the Form 4 filing with the SEC, Villacrez has control over a total of 454 common shares of the company, with 454 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1051512/000192629725000006/xslF345X05/wk-form4_1755548903.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CorMedix Completes Acquisition of Melinta Therapeutics; Updates 2025 Revenue Outlook
CorMedix Completes Acquisition of Melinta Therapeutics; Updates 2025 Revenue Outlook
Sep 2, 2025
08:32 AM EDT, 09/02/2025 (MT Newswires) -- CorMedix ( CRMD ) said Tuesday it has completed the purchase of Melinta Therapeutics. The company paid $300 million in upfront payment, comprised of $260 million in cash and $40 million in Cormediz equity issued to Deerfield Management. The agreement also consists additional regulatory milestone payment of up to $25 million for the...
Johnson & Johnson Says Varipure Showed 'Strong' Safety Outcomes in Pulsed Field Ablation Procedures
Johnson & Johnson Says Varipure Showed 'Strong' Safety Outcomes in Pulsed Field Ablation Procedures
Sep 2, 2025
08:37 AM EDT, 09/02/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that a substudy evaluating its Varipulse platform for pulsed field ablation procedures for atrial fibrillation demonstrated a strong safety profile, a 99.7% acute effectiveness, and procedural efficiency among 791 patients. The company said that the Varipulse platform, which consists of the Varipulse catheter and Trupulse...
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab
Sep 2, 2025
08:35 AM EDT, 09/02/2025 (MT Newswires) -- Zenas BioPharma ( ZBIO ) and Royalty Pharma ( RPRX ) said Tuesday that the latter will offer up to $300 million in financing in exchange for a royalty on sales of monoclonal antibody obexelimab. Obexelimab is in phase 3 development to treat immunoglobulin G4-related disease (IgG4-RD), and phase 2 development for relapsing...
Editas Medicine Picks EDIT-401 Gene Editing Drug as Lead In Vivo Development Candidate
Editas Medicine Picks EDIT-401 Gene Editing Drug as Lead In Vivo Development Candidate
Sep 2, 2025
08:33 AM EDT, 09/02/2025 (MT Newswires) -- Editas Medicine ( EDIT ) said Tuesday it has nominated EDIT-401, an LDLR-targeted therapy for hyperlipidemia, as its lead in vivo development candidate. The experimental treatment reduced LDL cholesterol by nearly 90% with a single dose in non-human primates, the company said. EDIT-401 is designed as a one-time gene editing therapy to increase...
Copyright 2023-2026 - www.financetom.com All Rights Reserved